DK3129016T3 - Nye cellepermeable succinatforbindelser - Google Patents

Nye cellepermeable succinatforbindelser Download PDF

Info

Publication number
DK3129016T3
DK3129016T3 DK15714820.6T DK15714820T DK3129016T3 DK 3129016 T3 DK3129016 T3 DK 3129016T3 DK 15714820 T DK15714820 T DK 15714820T DK 3129016 T3 DK3129016 T3 DK 3129016T3
Authority
DK
Denmark
Prior art keywords
butyl
propyl
formula
mitochondrial
complex
Prior art date
Application number
DK15714820.6T
Other languages
English (en)
Inventor
Eskil Elmér
Magnus Joakim Hansson
Karl Henrik Johannes Ehinger
Steven Moss
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58804197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3129016(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Application granted granted Critical
Publication of DK3129016T3 publication Critical patent/DK3129016T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/18—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Claims (15)

  1. 1. Forbindelse ifølge opfindelsen angivet ved formlen (I) o o ΑΛ 0) eller et farmaceutisk acceptabelt salt deraf, hvor den punkterede binding mellem A og B betegner en eventuel binding til dannelse af en lukket ringstruktur, og hvor Z er valgt fra -CH2-CH2- eller >CH(CH3), A er valgt fra -SR, -OR og NHR, og R er o o Λ Λ Rf NH Xf X Νδ A π ^15 ' ' η θ||θ|" R1?14 Β er valgt fra -O-R', -NHR”, -SR'” eller -OH; og R' er valgt fra formlen (II) til (IX) nedenfor: O R, r2A^ r3 (II) o (V) Rf Rg-^-4 Rh (|X) R', R” og R”' er uafhængigt forskellige eller identiske og er valgt fra formel (IV-VIII) nedenfor: 0 2 X X RfNH Xf X R-JS / ' n K15 A n ri3rm (vil) eller
    o
    (VIII) Ri og R3 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, CH2Xalkyl, CH2Xacyl, F, CH2COOH, CH2CO2alkyl, X er valgt fra O, NH, NRe, S, R2 er valgt fra Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, C(O)CH3, C(O)CH2C(O)CH3, C(O)CH2CH(OH)CH3, p er et heltal og er 1 eller 2 Re er valgt fra H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, acyl, propi-onyl, benzoyl, eller formel (II), eller formel (VIII) X5 er valgt fra -H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, -COOH, C(=O)XRe, , CONR1R3 eller er formel H N'\, O O O H X7 er valgt fra Ri, -NR1R3, Rg er valgt fra H, Me, Et eller O2CCH2CH2COXR8 R10 er valgt fra Oacyl, NHalkyl, NHacyl, eller O2CCH2CH2COX6R8 Xe er valgt fra O, NRs, NReRs, hvor Re og Rs er uafhængigt forskellige eller identiske og er valgt fra H, alkyl, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, acyl, propionyl, benzoyl, eller formel (II), eller formel (VIII), R11 og R12 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, propionyl, benzoyl, -CH2Xalkyl, - CH2Xacyl, hvor X er O, NR6 eller S,
    Rc og Rd er uafhængigt forskellige eller identiske og er valgt fra CH2Xalkyl, CH2Xa-cyl, hvor X = O, NRe eller S, R13, Ru og R15 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, -COOH, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, CH2Xalkyl; substituenter på R13 og R14 eller R13 og R15 kan danne bro til dannelse af et ringsystem, Rf, Rg og Rh er uafhængigt forskellige eller identiske og er valgt fra Xacyl, -CH2Xalkyl, -CH2X-acyl og Rg, alkyl er valgt fra Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acyl er valgt fra formyl, acetyl, propionyl, isopropionyl, butyryl, tert-butyryl, penta-noyl, benzoyl, acyl og/eller alkyl kan eventuelt være substitueret, og når den punkterede binding mellem A og B er til stede, er forbindelsen med formel (I) γχ4 O K1 hvor X4 er valgt fra -COOH, -C(=O)XRe, H nA o o o li ,N il w ’ H med det forbehold, at forbindelsen ikke er o o H o eller NHAc O NH2 O o o eller o o
  2. 2. Forbindelse ifølge krav 1 med formlen (IA) o o Α^'Ά (|A) eller et farmaceutisk acceptabelt salt deraf, hvor Z er -CH2-CH2-, A er valgt fra -SR, -OR og NHR, og R er o o Λ A Fif NH X7^ X t r!?A eller R1B14 B er valgt fra -O-R', -NHR", -SR'" eller -OH; og R', R" og R'" er uafhængigt forskellige eller identiske og er valgt fra en af formlerne nedenfor: o o Ri NH At At Ri3R?4 (VII) eller Rt^ Ri og R3 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, O-Me, Ο-Et, O-propyl, X er valgt fra O, NH, S, p er et heltal og er 1, Re er valgt fra H, Me, Et, Xs er valgt fra -H, Me, Et, -COOH, -C(=O)XR6, -CONR1R3 X7 er valgt fra Ri, -NR1R3,
    R13, Ru og R15 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, -COOH, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, CH2Xalkyl, hvor alkyl og acyl er som defineret ovenfor.
  3. 3. Forbindelse ifølge krav 1 eller 2 med formel (IA) o o aAzAb eller et farmaceutisk acceptabelt salt deraf, hvor Z er -CH2-CH2-, A er valgt fra -SR, -OR og NHR, og R er o o A A Rf NH . X? X R,s«, θ||θΓ R,A, B er valgt fra -O-R', -NHR", -SR'" eller -OH; og R', R" og R'" er uafhængigt forskellige eller identiske og er valgt fra én af formlerne nedenfor: θ 2 A A R-AnH x? x , R13R14 (Vil) eller J Ri og R3 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, propyl, O-Me, Ο-Et, O-propyl, X er valgt fra O, NH, S, p er et heltal og er 1, Re er valgt fra H, Me, Et, X5 er valgt fra -H, Me, Et, -COOH, -C(=O)ORe, , CONR1R3, X7 er valgt fra Ri, -NR1R3,
    R13, Ru og R15 er uafhængigt forskellige eller identiske og er valgt fra H, Me, Et, -COOH.
  4. 4. Forbindelse ifølge ethvert af de foregående krav, hvor Z er -CH2CH2-, og A er -SR.
  5. 5. Forbindelse ifølge ethvert af de foregående krav, hvor Z er -CH2CH2-, A er -SR, og B er OH eller SR'".
  6. 6. Forbindelse ifølge ethvert af de foregående krav, hvor Z er -CH2CH2-, A er -SR, B er OH eller SR'", hvor R'" er X r13r£, .
  7. 7. Forbindelse ifølge ethvert af de foregående krav, hvor Z er -CH2CH2, og A er SR, og B er OH.
  8. 8. Forbindelse ifølge ethvert af kravene 1 -3, hvor Z er -CH2CH2-, A er NR, B er OH, og R er o x/^x og X er S.
  9. 9. Forbindelse ifølge ethvert af de foregående krav, hvor R og/eller R'" er o Ϊ R-;NH og p=1, og X5 er -H, således at formel (VII) er o X RfXH RnFft (VII)
  10. 10. Forbindelse ifølge ethvert af kravene 1-8, hvor R og/eller R'" er Rl3F% ,
    og p=1, og X5 er COXRe, således at formel (VII) er o Λ Rf ONH Κκ-χςΜχΑ R13RT4 (VII)
  11. 11. Forbindelse ifølge ethvert af kravene 1 -8, hvor R og/eller R'" er o Rj^NH R13R& (Vil) og p=1, og X5 er CONR1R3, således at formel (VII) er o X R/σΝΗ f/ «15 /\ D R3 r13rV (VII).
  12. 12. Forbindelse ifølge ethvert af de foregående krav, hvor forbindelsen er valgt fra: o A/ O o o o O Α^λΑη O O H o H O O o o ΗΝ'Ά"'' O \ / O ΗΟΥ\Υγ5··-γθΗ ΗΟγ^^δ~-^γ' h°y^AsA> O O O O o ΗΝγχ- O O r o ° o o o o Αχ ° HO^ÅsX^r O O HN O ' O /-γΝΗ O O O “yAXjA ΗΟγ^Χ^Νγ. HO^XX^ Y O o O o o Y ^5^ΛθΗ Υ^γχΛΟΗ HO^XV 1 h O O o O O O o o o o Ho^YrsYSfOH 'ΆΑ^υ^Λοη ΛΧδγ%Λ0Η o Λ o H g Η f j
    A-YVxAon Λ-γγ-Λ« Λ-γγΛ O O unÅh ΛΝ^γ^ΑΟΗ Ογ® 0
  13. 13. Forbindelse ifølge ethvert af kravene 1 -12 til anvendelse i medicin.
  14. 14. Forbindelse ifølge ethvert af kravene 1 -12 til anvendelse i kosmetik.
  15. 15. Sammensætning indeholdende en forbindelse med formel (I) som defineret ifølge ethvert af kravene 1 -12 og ét eller flere farmaceutisk eller kosmetisk acceptable excipienser.
DK15714820.6T 2014-04-08 2015-04-08 Nye cellepermeable succinatforbindelser DK3129016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470190 2014-04-08
PCT/EP2015/057606 WO2015155231A1 (en) 2014-04-08 2015-04-08 Novel cell-permeable succinate compounds

Publications (1)

Publication Number Publication Date
DK3129016T3 true DK3129016T3 (da) 2018-09-03

Family

ID=58804197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15714820.6T DK3129016T3 (da) 2014-04-08 2015-04-08 Nye cellepermeable succinatforbindelser

Country Status (25)

Country Link
US (2) US11147789B2 (da)
EP (2) EP3129016B1 (da)
JP (4) JP7082861B6 (da)
KR (1) KR102322543B1 (da)
CN (1) CN106458957B (da)
AU (2) AU2015243346C9 (da)
CA (1) CA2944565C (da)
CY (1) CY1120650T1 (da)
DK (1) DK3129016T3 (da)
EA (1) EA035678B1 (da)
ES (2) ES2683860T3 (da)
HR (1) HRP20181126T1 (da)
IL (1) IL247904B (da)
LT (2) LT3391941T (da)
MA (2) MA44092B1 (da)
MX (1) MX378072B (da)
PL (1) PL3129016T3 (da)
PT (2) PT3129016T (da)
RS (1) RS57624B1 (da)
SG (1) SG11201607907PA (da)
SI (1) SI3129016T1 (da)
SM (1) SMT201800429T1 (da)
TR (1) TR201810411T4 (da)
WO (1) WO2015155231A1 (da)
ZA (1) ZA201606608B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39856A (fr) * 2014-04-08 2017-02-15 Neurovive Pharmaceutical Ab Promédicaments d'acide succinique pour augmenter la production d'atp
WO2015155238A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
TR201810411T4 (tr) * 2014-04-08 2018-08-27 Neurovive Pharmaceutical Ab Özgün hücre geçirgen süksinat bileşikleri.
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
WO2017060420A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
WO2017096270A1 (en) 2015-12-03 2017-06-08 The Regents Of The University Of California Methods for treating mitochondrial diseases
CA3113071A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and methods of use thereof
CN112888419A (zh) * 2018-10-11 2021-06-01 安布里亚制药公司 用于治疗和预防Leber遗传性视神经病变的组合物和方法
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756422A (en) * 1950-09-14 1956-09-05 Saint Gobain Esters of urethanes of glycols and the manufacture thereof
NL6806584A (da) * 1965-09-20 1968-11-12
FR2265355B1 (da) * 1974-03-28 1977-11-04 Blum Jean
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
DE4101158C2 (de) * 1991-01-14 1994-06-23 Dainippon Ink & Chemicals Wärmehärtbare Reaktionsharzgemische, Verwendung der erfindungsgemäßen Reaktionsharze zur Herstellung von Formkörpern und Beschichtungen
CA2107581A1 (en) 1992-02-07 1993-08-08 Kiyoshi Sugiyama Side-effect alleviant
JPH07331262A (ja) * 1994-05-31 1995-12-19 Tonen Corp パティキュレート低減用添加剤及び該添加剤を用いたディーゼルエンジン用燃料組成物
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
CA2341640A1 (en) 1998-07-02 2000-01-13 Chaitan Khosla Methods for making polyketides using altered pks
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
EP1401850A1 (en) * 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100791844B1 (ko) 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
US20120308646A1 (en) * 2007-01-18 2012-12-06 Hesheng Zhang Tetracyclic anthraquinones possessing anti-cancer properties
EP2139320A4 (en) 2007-03-26 2010-09-08 Salutria Pharmaceuticals Llc METHODS AND COMPOSITIONS OF PROBUCOL DERIVATIVES FOR THE TREATMENT OF DIABETES
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
WO2014053857A1 (en) 2012-10-05 2014-04-10 Mitopharm Ltd Protected succinates for enhancing mitochondrial atp-production
TR201810411T4 (tr) * 2014-04-08 2018-08-27 Neurovive Pharmaceutical Ab Özgün hücre geçirgen süksinat bileşikleri.
WO2015155238A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
MA39856A (fr) 2014-04-08 2017-02-15 Neurovive Pharmaceutical Ab Promédicaments d'acide succinique pour augmenter la production d'atp

Also Published As

Publication number Publication date
SI3129016T1 (sl) 2018-10-30
SG11201607907PA (en) 2016-10-28
CN106458957B (zh) 2020-08-18
JP7082861B2 (ja) 2022-06-09
JP7229189B2 (ja) 2023-02-27
EA201692017A1 (ru) 2017-02-28
CY1120650T1 (el) 2019-12-11
AU2015243346C9 (en) 2019-03-07
MX378072B (es) 2025-03-10
AU2018282308A1 (en) 2019-01-17
AU2015243346C1 (en) 2019-02-07
JP7082861B6 (ja) 2023-12-22
BR112016023086A2 (pt) 2017-08-15
ZA201606608B (en) 2022-10-26
EP3129016B1 (en) 2018-06-06
ES2683860T3 (es) 2018-09-28
IL247904B (en) 2020-08-31
EP3129016A1 (en) 2017-02-15
AU2015243346A1 (en) 2016-10-13
US20210401792A1 (en) 2021-12-30
SMT201800429T1 (it) 2018-09-13
RS57624B1 (sr) 2018-11-30
WO2015155231A1 (en) 2015-10-15
JP2020100628A (ja) 2020-07-02
MX2016012691A (es) 2016-12-16
KR20160142861A (ko) 2016-12-13
CN106458957A (zh) 2017-02-22
PT3129016T (pt) 2018-10-01
CA2944565A1 (en) 2015-10-15
JP2021169518A (ja) 2021-10-28
KR102322543B1 (ko) 2021-11-04
US20170105961A1 (en) 2017-04-20
HRP20181126T1 (hr) 2018-10-05
MA44092B1 (fr) 2023-08-31
JP2021169519A (ja) 2021-10-28
US12310940B2 (en) 2025-05-27
MA39855A (fr) 2018-10-24
PL3129016T3 (pl) 2018-10-31
EA035678B1 (ru) 2020-07-24
ES2953522T3 (es) 2023-11-14
IL247904A0 (en) 2016-11-30
CA2944565C (en) 2022-11-29
JP2017513829A (ja) 2017-06-01
HK1255109A1 (en) 2019-08-02
BR112016023086A8 (pt) 2021-06-29
EP3391941A1 (en) 2018-10-24
LT3129016T (lt) 2018-09-10
MA39855B1 (fr) 2018-10-31
PT3391941T (pt) 2023-08-24
LT3391941T (lt) 2023-11-10
US11147789B2 (en) 2021-10-19
TR201810411T4 (tr) 2018-08-27
AU2015243346B2 (en) 2018-10-18
EP3391941B1 (en) 2023-06-07
AU2018282308B2 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US12310940B2 (en) Cell-permeable succinate compounds
US20170105960A1 (en) Prodrugs of Succinic Acid for Increasing ATP Production
AU2015243353A1 (en) Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
HK1255109B (en) Novel cell-permeable succinate compounds
HK1228251A1 (en) Novel cell-permeable succinate compounds
HK1228251B (en) Novel cell-permeable succinate compounds
BR112016023086B1 (pt) Composto, composição, e, uso de um composto
WO2017060422A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders